Taiwan The co-founder and president of Mycenax Biotech, Dr. Karen Wen details the key lessons learned from the development of their first in-house product TuNEX® and how they have been applied to their second flagship product LusiNEX (tocilizumab). She also details the company’s transition from a platform-driven service provider to a…
Greece A strong proponent of the value of orphan drugs, Shire Greece’s Managing Director, Christos Dakas, shares his insights on the recent merger with Baxalta, the necessity of exempting orphan and haemophilia drugs from clawbacks to circumvent market challenges for critical treatments, as well as his vision for the bright future…
Taiwan Chih-Kung Lee, Minister of Economic Affairs of the Republic of China (Taiwan) provides insights into Taiwan’s “new economic model” recently established by the new government to boost the country’s economic growth and ensure Taiwan renews its role as an innovation pioneer. He also documents the crucial role that the pharmaceutical…
Taiwan Lawrence Gan, President and CEO of Taiwan’s Development Center for Biotechnology (DCB) explains his vision and strategy to enhance DCB’s R&D expertise by adopting some of the best practices of the corporate world. You became head of Taiwan’s Development Center for Biotechnology after having held prestigious positions in the US…
Taiwan Thomas Yuan, the CEO of TFBS Bioscience, documents the tailored added-value that this fast-growing product testing company strives to bring to emerging pharmaceutical and biotech companies in the Asia Pacific region, while TFBS already stands out as the only service provider of its kind in Taiwan and one of the…
Switzerland How would you present the strengths of the Lake Geneva region’s strengths to our international audience? The Lake Geneva region, which we often call the ‘health valley of Switzerland’, benefits from having two intersecting innovative clusters, one in MedTech and another in biotech. Looking at the course of life sciences…
Pharma 2016 has been a great year for PharmaBoardroom, with interviews from global CEOs and ministers, groundbreaking country reports on some of the world’s key pharma markets, and insightful articles which get to the heart of the sector’s key issues. Stay tuned in 2017 for more of the same! INTERVIEWS OF…
Ireland Frederic Secail, General Manager of Servier’s second strategic and international production facility within Servier Industry, located in Arklow, Ireland, outlines his ambitious transformation program, Arklow 2020, to anticipate and prepare the site for the future. You have been GM of Servier’s Arklow facility since 2013. What was the mandate given…
Mexico Salomon Rayek, CEO at Sinbiotik, explains how the company managed to adapt its business model to the industry trends and showcases the added value of Sinbiotik when offering high quality, cost-effective and fully regulated APIs manufactured locally. Could you please introduce yourself to our international audience as well as the…
Ireland James Lennertz, Group VP and GM EUMEA for BioMarin, discusses the key highlights of the past few years for BioMarin, their unique positioning as a company offering innovative therapies for ultra-rare diseases, the main challenge he sees for BioMarin’s international operations, and his priorities for the next few years. James,…
Switzerland The Swiss Biotech Association’s Nic Alexakis describes Switzerland’s thriving biotech scene and extensive support infrastructure, while also highlighting the gaps around early stage funding and the ability of different cantons to collaborate on economic development. Switzerland of course has quite the reputation as a hub for biotech activity – how…
Actelion Johnson & Jonhson’s interest in taking over the Swiss biotech group Actelion has been confirmed, with the Wall Street Journal estimating that a total takeover price could top USD 20 billion. As Actelion is a market leader in some therapeutic areas such as pulmonary arterial hypertension (PAH), the acquisition could…
See our Cookie Privacy Policy Here